趋化因子是免疫系统不可或缺的组成部分，与炎症性肠病（IBD）和结直肠癌（CRC）的发病机制和进展密切相关。尽管已经积累了大量关于这些疾病的转录组数据，但其中大多数仅限于疾病的特定阶段。本研究的目的是通过整合相关数据集，直观地展示肠道疾病各个阶段趋化因子的动态变化。整合IBD和CRC的现有数据集，我们比较了不同病理阶段趋化因子的表达变化。这项研究收集了来自世界各地各个医疗中心的 11 个临床数据库。患者：根据出版商的注释，患者组织类型数据分为IBD、结直肠腺瘤、原发癌、转移瘤和健康对照。对各病理阶段趋化因子的表达变化进行统计分析。趋化因子按不同的表达模式聚集。趋化因子家族分为四种不同的表达模式，对应于结肠炎和肿瘤发展不同阶段的不同表达变化。已鉴定出与炎症和肿瘤发生相关的某些趋化因子和受体。此外，还证实2,4,6-三硝基苯磺酸（TNBS）诱导的结肠炎模型和氧化偶氮甲烷（AOM）/硫酸葡聚糖硫酸钠（DSS）诱导的结肠癌模型在以下方面与临床数据显示出更强的相关性：趋化因子表达水平。该研究全景展示了从IBD到晚期结肠癌多个阶段趋化因子家族的表达谱，有助于全面了解趋化因子的调控模式，指导药物研发方向。这项研究为研究人员提供了炎症性肠病和结肠癌病理过程中趋化因子表达的清晰图谱。

Chemokines are integral components of the immune system and deeply involved in the pathogenesis and progression of inflammatory bowel disease (IBD) and colorectal cancer (CRC). Although a considerable amount of transcriptome data has been accumulated on these diseases, most of them are limited to a specific stage of the disease. The purpose of this study is to visually demonstrate the dynamic changes in chemokines across various stages of bowel diseases by integrating relevant datasets. Integrating the existing datasets for IBD and CRC, we compare the expression changes of chemokines across different pathological stages. This study collected 11 clinical databases from various medical centers around the world. Patients: Data of patient tissue types were classified into IBD, colorectal adenoma, primary carcinoma, metastasis, and healthy control according to the publisher's annotation. The expression changes in chemokines in various pathological stages are statistically analyzed. The chemokines were clustered by different expression patterns. The chemokine family was clustered into four distinct expression patterns, which correspond to varying expression changes in different stages of colitis and tumor development. Certain chemokines and receptors associated with inflammation and tumorigenesis have been identified. Furthermore, it was confirmed that the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model and the azoxymethane (AOM)/ dextran sulfate sodium (DSS)-induced colon cancer model shows stronger correlations with the clinical data in terms of chemokine expression levels. This study paints a panoramic picture of the expression profiles of chemokine families at multiple stages from IBD to advanced colon cancer, facilitating a comprehensive understanding of the regulation patterns of chemokines and guiding the direction of drug development. This study provides researchers with a clear atlas of chemokine expression in the pathological processes of inflammatory bowel disease and colon cancer.